In our study we used orlistat, an anti-obesity drug that inhibits pancreatic lipases, and was later discovered also to irreversibly inhibit the thioesterase domain of FASN, which does not result in accumulation of cytotoxic intermediates of FA synthesis [51]. This evidence concerns the gene FASN and obesity disorder.